Key Points
- Enliven Therapeutics CFO Benjamin Hohl sold 6,018 shares on June 17 at an average price of $43.80, totaling about $263,588. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and he still owned 51,000 shares afterward.
- ELVN shares were up 1.9% and opened at $45.96, near the stock’s 52-week high of $48.53. The company now has a market cap of about $2.8 billion.
- Recent results and analyst sentiment remain positive: Enliven beat quarterly EPS estimates with a loss of ($0.38) vs. ($0.44) expected, and Wall Street’s consensus rating is Moderate Buy with an average target price of $63.40.
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 6,018 shares of the firm's stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total value of $263,588.40. Following the completion of the sale, the chief financial officer owned 51,000 shares in the company, valued at approximately $2,233,800. This represents a 10.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Enliven Therapeutics Stock Up 1.9%
Shares of NASDAQ ELVN opened at $45.96 on Tuesday. The stock has a market cap of $2.80 billion, a P/E ratio of -27.52 and a beta of 0.29. The firm's 50-day simple moving average is $41.82 and its 200 day simple moving average is $31.76. Enliven Therapeutics, Inc. has a fifty-two week low of $14.78 and a fifty-two week high of $48.53.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.44) by $0.06. On average, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.71 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Enliven Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the stock. HighVista Strategies LLC lifted its holdings in Enliven Therapeutics by 83.1% during the 3rd quarter. HighVista Strategies LLC now owns 259,135 shares of the company's stock valued at $5,304,000 after purchasing an additional 117,619 shares during the last quarter. Tudor Investment Corp ET AL acquired a new position in Enliven Therapeutics during the 3rd quarter worth $334,000. Spruce Street Capital LP acquired a new position in shares of Enliven Therapeutics during the fourth quarter valued at $6,870,000. Baker BROS. Advisors LP lifted its position in Enliven Therapeutics by 136.3% during the 4th quarter. Baker BROS. Advisors LP now owns 271,406 shares of the company's stock valued at $4,180,000 after purchasing an additional 156,573 shares during the period. Finally, Seven Fleet Capital Management LP acquired a new position in Enliven Therapeutics in the fourth quarter valued at approximately $180,000. Institutional investors own 95.08% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on the company. HC Wainwright upped their price target on Enliven Therapeutics from $48.00 to $56.00 and gave the company a "buy" rating in a report on Thursday, March 26th. The Goldman Sachs Group increased their target price on shares of Enliven Therapeutics from $41.00 to $59.00 and gave the stock a "buy" rating in a research report on Friday, May 8th. Mizuho raised their price target on Enliven Therapeutics from $45.00 to $62.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 2nd. Guggenheim began coverage on shares of Enliven Therapeutics in a research note on Tuesday, May 12th. They issued a "buy" rating and a $80.00 price objective for the company. Finally, Wall Street Zen upgraded Enliven Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Enliven Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $63.40.
Get Our Latest Research Report on Enliven Therapeutics
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.
The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
